136 related articles for article (PubMed ID: 38469780)
21. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract][Full Text] [Related]
22. Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
Chen D; Chen W
Br J Haematol; 2021 May; 193(4):691. PubMed ID: 33386742
[No Abstract] [Full Text] [Related]
23. Machine learning derived genomics driven prognostication for acute myeloid leukemia with
Shaikh AF; Kakirde C; Dhamne C; Bhanshe P; Joshi S; Chaudhary S; Chatterjee G; Tembhare P; Prasad M; Roy Moulik N; Gokarn A; Bonda A; Nayak L; Punatkar S; Jain H; Bagal B; Shetty D; Sengar M; Narula G; Khattry N; Banavali S; Gujral S; P G S; Patkar N
Leuk Lymphoma; 2020 Dec; 61(13):3154-3160. PubMed ID: 32757686
[TBL] [Abstract][Full Text] [Related]
24. Hemophagocytic Lymphohistiocytosis in
Huang X; Long F; Zhang Y; Gao X; Li T
Turk J Haematol; 2023 Aug; 40(3):210-212. PubMed ID: 37519108
[No Abstract] [Full Text] [Related]
25. Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.
Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerland MC; Berdel WE; Wörmann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix AL
Sci Rep; 2018 Jul; 8(1):11293. PubMed ID: 30050054
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ
Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Prognostic Factors Analysis of Initially Treated AML Children with t(8;21)/RUNX1-RUNX1T1
Fan GL; Jiang PJ; Yuan M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1510-1515. PubMed ID: 33067946
[TBL] [Abstract][Full Text] [Related]
28. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
30. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome.
Gustafson SA; Lin P; Chen SS; Chen L; Abruzzo LV; Luthra R; Medeiros LJ; Wang SA
Am J Clin Pathol; 2009 May; 131(5):647-55. PubMed ID: 19369623
[TBL] [Abstract][Full Text] [Related]
31. A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1.
Yamamoto K; Yakushijin K; Funakoshi Y; Sanada Y; Kawamoto S; Matsuoka H; Minami H
J Clin Exp Hematop; 2014; 54(2):167-70. PubMed ID: 25318951
[No Abstract] [Full Text] [Related]
32. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract][Full Text] [Related]
33. Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules.
Kondo H; Kanayama T; Matsumura U; Urata T; Osone S; Imamura T; Inaba T; Hosoi H
Int J Hematol; 2021 May; 113(5):616-617. PubMed ID: 33782817
[No Abstract] [Full Text] [Related]
34. Identification of a new translocation that disrupts the RUNX1 gene in a patient with de novo acute myeloid leukemia.
Lucena-Araujo AR; de Figueiredo-Pontes LL; de Oliveira FM; de Lourdes Chauffaille M; Falcao RP; Rego EM
Med Oncol; 2012 Jun; 29(2):1114-8. PubMed ID: 21380778
[TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
36. Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature.
Kim H; Moon HW; Hur M; Yun YM; Lee MH
Acta Haematol; 2011; 125(4):237-41. PubMed ID: 21325813
[TBL] [Abstract][Full Text] [Related]
37. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
38. RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22).
Ismael O; Shimada A; Elmahdi S; Elshazley M; Muramatsu H; Hama A; Takahashi Y; Yamada M; Yamashita Y; Horide K; Kojima S
Int J Hematol; 2014 Feb; 99(2):169-74. PubMed ID: 24374719
[TBL] [Abstract][Full Text] [Related]
39. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
[TBL] [Abstract][Full Text] [Related]
40. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
Wang Y; Wu DP; Liu QF; Qin YZ; Wang JB; Xu LP; Liu YR; Zhu HH; Chen J; Dai M; Huang XJ
Blood; 2014 Sep; 124(12):1880-6. PubMed ID: 25082877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
